patient, although no additional mutations were found in this patient to account for the WWS phenotype. Recently, this mutation was found in heterozygosity in an Italian patient diagnosed with congenital muscular dystrophy and mental retardation who also carried another mutation in the POMT1 coding region, raising the possibility that this is a hotmutation site in the gene. Western blotting revealed a complete lack of glycosylated α-DG, which was confirmed by laminin overlay assay, while β-DG detection was normal (data not shown). Immunohistochemical analysis of muscle biopsies with VIA-4 antibody corroborated the alpha-dystroglycanopathy in both patients. However, the α-DG core protein was correctly located at the plasma membrane as assessed by the pαDAG antibody and distributed within the cell, probably undergoing post-translational modifications. Immunolabelling of β-DG and laminin was normal. POMT1 is an integral endoplasmic reticulum (ER) membrane protein distributed in a similar pattern to the ER-marker calnexin. In muscle cells, the sarcoplasmic reticulum (SR) forms a network around the transverse T tubules that is continuous with the plasma membrane. In controls, POMT1 and calnexin were detected in the SR as part of this network within the muscle cell, as well as in the subsarcolemic space. While the distribution of calnexin did not appear to change in patients 1.1 and 2.1, POMT1 was only located in certain parts of the subsarcolemma and diffusely within the cell. The mutation g.3553G>T removes exon 4 from the POMT1 transcript of patients 1.1 and 2.1 while preserving the open reading frame and the epitope recognized by the anti-POMT1 antibody in Loop 5. Nevertheless, the distribution of POMT1 is altered, and it no longer co-localizes with calnexin, implying it has lost its ER-localization. This could be due to conformational changes in the POMT1 protein or to the degradation of the mutated protein inside the muscle cell. Staining for calnexin dismisses any major alterations to the SR in these patients. Of these two mutations, the one causing exon 4 skipping is likely to be the most relevant for the WWS phenotype. In the second mutation, the substituted Ser515 is not very conserved and patients carrying this mutation do not provide much information about its relevance as none are homozygous carriers. Thus, although disease causing, this mutation might be responsible for milder phenotypes if not accompanied by a more severe change. Founder effects have been reported for genes causing dystroglycanopathies in close-knit populations and less so in families with no defined inbreeding. We recently reported a potential founder mutation in the fukutin gene in the Ashkenazi Jewish population that was subsequently confirmed in a larger study. Since both our subjects carrying the same homozygous mutations belong to unrelated Gypsy families, the mutations identified here could reflect a possible founder effect in the POMT1 gene within the Spanish Gypsy population. Patients 1.1 and 2.1 came from families with a high degree of consanguinity and thus, it is likely that the parents of both patients were heterozygous carriers of the mutations. Unfortunately, no samples from the parents were available for studies. Inbreeding is very common in the Gypsy population, manifesting a high prevalence of phenotypes caused by recessive mutations and the transmission of these mutations. Further studies will be necessary to determine if this double mutation in the POMT1 gene is widespread among the Spanish Gypsy population.
